NanoVibronix Raises Up to $50 Million in Preferred Stock Financing for Market Expansion, Product Development, and Debt Redemption.

NanoVibronix has secured up to $50 million in private placement financing for preferred stock. The initial $8 million will be used for market expansion, product development, and redemption of Series X Preferred Stock. The company plans to use the funds to expand its footprint in high-impact markets and drive sustainable growth. The financing is expected to be completed on or about July 21, 2025.

NanoVibronix, Inc. (NASDAQ: NAOV), a medical technology company specializing in therapeutic devices for enteral feeding, pain management, and urological conditions, has announced the completion of a significant private placement of preferred stock, totaling up to $50 million. The company expects to raise $8 million upfront, with the potential for an additional $40 million from the exercise of additional investment rights [1]. The transaction is expected to close on or about July 21, 2025, subject to customary closing conditions [1].

The initial gross proceeds of $8 million will be used to redeem $5 million in outstanding shares of Series X Preferred Stock and to allocate $3 million for working capital purposes. Additionally, the company has agreed to issue an additional $2 million in gross proceeds from a second closing, also subject to customary conditions [1].

NanoVibronix aims to use the funds to expand its market footprint, accelerate growth, and invest in products with high potential for driving sustainable growth and long-term shareholder value. The company's innovative solutions address critical gaps in current standard-of-care practices, improve patient outcomes, and reduce healthcare complications.

Doron Besser, M.D., Chief Executive Officer of NanoVibronix, stated, "This capital empowers us to expand our footprint in high-impact, large addressable markets, scale more rapidly and invest in products with the greatest potential to drive sustainable growth and long-term shareholder value. Our innovative solutions address critical gaps in current standard-of-care practices, improve patient outcomes and reduce healthcare complications. With strong momentum behind our lead technologies, a clear roadmap for execution and additional financial resources, we believe we are well-positioned to capture a meaningful share of an enormous market and deliver long-term value for our shareholders."

The securities offered in this private placement, and the shares of common stock issuable upon conversion of the Preferred Stock, are being offered in reliance upon an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement and shares of common stock issuable upon conversion of the Preferred Stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

NanoVibronix has a strong pipeline of innovative technologies, including Acoustic-based therapeutic technologies and ENvue™ Navigation Platform, which are intended to address critical healthcare needs and improve patient outcomes.

The company's forward-looking statements are subject to various known and unknown risks and uncertainties, including market acceptance of its existing and new products, clinical performance and operational outcomes, delays or complications in product implementation, intense competition in the medical device industry, product liability or performance issues, limitations in manufacturing or supply chain capabilities, reimbursement limitations, intellectual property protection, healthcare regulatory changes in the U.S. and abroad, and the need for additional capital.

For more detailed information about the Company and the risk factors that may affect the realization of forward-looking statements, investors and security holders are urged to read the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which are available free of charge at www.sec.gov.

References:
[1] https://finance.yahoo.com/news/nanovibronix-announces-financing-50-million-130000546.html
[2] https://www.ainvest.com/news/nanovibronix-secures-50-million-financing-preferred-stock-2507/